Whatever your antibody discovery needs may be, from target validation to lead selection and preclinical efficacy and safety testing, JAX has the right services and solutions to generate the data you need to make informed decisions for your human-specific therapeutic antibody.
These fast, reliable, and translationally-relevant results can give you confidence earlier and de-risk the pipeline as you move toward your IND or commercialization goals.
No matter what class of engineered therapeutic antibody (antibody drug conjugates, bispecifics, etc.), we are here to help you design the right solution to get your therapy to IND filing.
Humanized FcRn platform is ideal for early evaluation of therapeutic candidates and inform clinical dosing. Our innovative efficacy platforms allow you to interrogate the interaction of your human specific therapeutic with its human cell and molecular targets in an in vivo setting.